Celyad Oncology SA
XBRU:CYAD
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.2295
1
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one CYAD stock under the Base Case scenario is 0.02 EUR. Compared to the current market price of 0.6 EUR, Celyad Oncology SA is Overvalued by 97%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Celyad Oncology SA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for CYAD cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Celyad Oncology SA
Balance Sheet Decomposition
Celyad Oncology SA
Current Assets | 11.1m |
Cash & Short-Term Investments | 7m |
Receivables | 2.8m |
Other Current Assets | 1.3m |
Non-Current Assets | 5.2m |
PP&E | 1.8m |
Intangibles | 390k |
Other Non-Current Assets | 2.9m |
Current Liabilities | 2.9m |
Accounts Payable | 1.2m |
Accrued Liabilities | 496k |
Other Current Liabilities | 1.2m |
Non-Current Liabilities | 7m |
Long-Term Debt | 902k |
Other Non-Current Liabilities | 6.1m |
Earnings Waterfall
Celyad Oncology SA
Revenue
|
72k
EUR
|
Cost of Revenue
|
-34k
EUR
|
Gross Profit
|
38k
EUR
|
Operating Expenses
|
-7.8m
EUR
|
Operating Income
|
-7.8m
EUR
|
Other Expenses
|
43k
EUR
|
Net Income
|
-7.8m
EUR
|
Free Cash Flow Analysis
Celyad Oncology SA
EUR | |
Free Cash Flow | EUR |
CYAD Profitability Score
Profitability Due Diligence
Celyad Oncology SA's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
Score
Celyad Oncology SA's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
CYAD Solvency Score
Solvency Due Diligence
Celyad Oncology SA's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Score
Celyad Oncology SA's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CYAD Price Targets Summary
Celyad Oncology SA
Dividends
Current shareholder yield for CYAD is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 88 full-time employees. The company went IPO on 2013-07-05. The firm is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The firm develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The firm's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). The company also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).
Contact
IPO
Employees
Officers
The intrinsic value of one CYAD stock under the Base Case scenario is 0.02 EUR.
Compared to the current market price of 0.6 EUR, Celyad Oncology SA is Overvalued by 97%.